Phase II STORM Trial: Selinexor + Dexamethasone Is Active in Patients With Heavily Pretreated Refractory MM

December 3-6, 2016; San Diego, California
First-in-class XPO1 inhibitor selinexor, in combination with low-dose dexamethasone, shows encouraging activity in heavily pretreated patients with MM refractory to multiple immunomodulatory agents, proteasome inhibitors, and anti-CD-38 monoclonal antibodies, according to the phase II STORM trial data.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.06 MB
Released: December 6, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 18, 2021

From Clinical Care Options (CCO), download slides reviewing the integration of CAR T-cell therapy for leukemias, lymphomas, and myeloma

Renier J. Brentjens, MD, PhD Frederick L. Locke, MD Noopur Raje, MD Released: February 11, 2021

Downloadable slides from Clinical Care Options (CCO) with key takeaway points on newly approved agents for multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: February 2, 2021

Downloadable slides from Clinical Care Options (CCO) with nurse expert’s insights on available treatments, new approvals, and adverse event managements in patients with multiple myeloma

Beth Faiman, PhD, MSN, APRN-BC, AOCN Charise Gleason, MSN, NP-BC, AOCNP Released: January 28, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue